iNtRON Biotechnology has announced that its New Drug Part has entered into an official contract with the U.S. Army DEVCOM (U.S. Army Combat Capabilities Development Command) International Technology Center Indo-Pacific and Solider Center to develop bacteriophages for combating Uropathogenic Escherichia coli (UPEC) infections.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.09 HKD | -2.34% | +0.97% | -5.86% |
21/03 | Intron Technology’s Profit Drops 24% in 2023 | MT |
20/03 | Intron Technology Holdings Limited Recommends Final Dividend for the Year Ended 31 December 2023, Payable on or About 2 July 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.86% | 291M | |
+22.24% | 48.55B | |
-7.74% | 22.52B | |
+29.45% | 20.68B | |
+35.73% | 17.83B | |
-4.22% | 15.03B | |
-18.11% | 13.48B | |
-20.85% | 13.11B | |
+34.67% | 12.1B | |
+36.99% | 10.73B |
- Stock Market
- Equities
- 1760 Stock
- News Intron Technology Holdings Limited
- INtRON Biotechnology Signs Bacteriophage Development Project with U.S. Army Devcom